

Docket No. X-15950

-2-

Amendments to the Claims

Please cancel claims 91 to 137 and add new claims 138 to 152.

138. A humanized antibody, or an antigen-binding portion thereof, that specifically binds human IL-1 β , selected from the group consisting of:

- (a) a light chain variable region comprising an amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:60 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:55;
- (b) a light chain variable region comprising an amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:61 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:56;
- (c) a light chain variable region comprising an amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:62 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:57;
- (d) a light chain variable region comprising an amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:63 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:58; and,
- (e) a light chain variable region comprising an amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:64 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:59;

139. A humanized antibody, or an antigen-binding portion thereof, that specifically binds human IL-1 β , comprising a light chain and a heavy chain selected from the group consisting of:

- (a) a light chain comprising an amino acid sequence of SEQ ID NO:46 and a heavy chain comprising an amino acid sequence of SEQ ID NO: 45;
- (b) a light chain comprising an amino acid sequence of SEQ ID NO:47 and a heavy chain comprising an amino acid sequence of SEQ ID NO: 48
- (c) a light chain comprising an amino acid sequence of SEQ ID NO:48 and a heavy chain comprising an amino acid sequence of SEQ ID NO:68;
- (d) a light chain comprising an amino acid sequence of SEQ ID NO:49 and a heavy chain comprising an amino acid sequence of SEQ ID NO:50;

Docket No. X-15950

-3-

(e) a light chain comprising an amino acid sequence of SEQ ID NO:51 and a heavy chain comprising an amino acid sequence of SEQ ID NO: 52; and,

(f) a light chain comprising an amino acid sequence of SEQ ID NO:53 and a heavy chain comprising an amino acid sequence of SEQ ID NO:54.

140. A humanized antibody, or an antigen-binding portion thereof, that specifically binds human IL-1 β , wherein said antibody has a light chain of SEQ ID NO: 48 and a heavy chain of SEQ ID NO:68.

141. An isolated nucleic acid comprising a polynucleotide encoding the antibody or antigen binding portion thereof, of Claim 138.

142. An expression vector comprising a nucleic acid according to Claim 141.

143. A host cell stably transfected with the expression vector of Claim 142.

144. A process for producing an antibody or antigen binding portion thereof, comprising cultivating the host cell of Claim 143 and recovering the polypeptide encoded by said polynucleotide from the culture.

145. A pharmaceutical composition comprising the antibody or antigen binding portion thereof of Claim 138.

146. A method of treating rheumatoid arthritis or osteoarthritis, comprising administering to a patient in need thereof an effective amount of the antibody or antigen binding portion thereof, of Claim 138.

147. An isolated nucleic acid, comprising a polynucleotide encoding the antibody or antigen binding portion thereof, of Claim 139.

148. An expression vector comprising a nucleic acid according to Claim 147.

149. A host cell stably transfected with the expression vector of Claim 148.

Docket No. X-15950

-4-

150. A process for producing an antibody or antigen binding portion thereof, comprising cultivating the host cell of Claim 149 and recovering the polypeptide encoded by said polynucleotide from the culture.


151. A pharmaceutical composition comprising the antibody or antigen binding portion thereof of Claim 139.

152. A method of treating rheumatoid arthritis or osteoarthritis, comprising administering to a patient in need thereof an effective amount of the antibody or antigen binding portion thereof, of Claim 139.

Remarks

Applicants maintain that Claims 138 – 152 add no new subject matter and are supported throughout the specification as originally filed.

Respectfully submitted,



Lynn D. Apelgren
Attorney for Applicants
Registration No. 45,341
Phone: 317-276-6501

Eli Lilly and Company
Patent Division/LDA
P.O. Box 6288
Indianapolis, Indiana 46206-6288
